A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511615-16-00

Acronym

SCD-044-19-16

Enrollment

Registered

2024-10-13

Start date

2023-08-25

Completion date

2024-11-25

Last updated

2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Brief summary

Proportion of subjects who achieve ≥75% overall improvement in EASI score from Baseline

Detailed description

Proportion of subjects who achieve score of '0' or '1' on a 5-point, vIGA scale and ≥2 point reduction from Baseline to Week 16

Interventions

DRUGSCD-044 Tablets 0.1mg

DRUGSCD-044 Tablets 0.6mg

DRUGSCD-044 Tablets 0.3mg

DRUGplacebo to match SCD-044 tablets

DRUGSCD-044 Tablets 1.0mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of subjects who achieve ≥75% overall improvement in EASI score from Baseline	—

Secondary

Measure	Time frame
Proportion of subjects who achieve score of '0' or '1' on a 5-point, vIGA scale and ≥2 point reduction from Baseline to Week 16	—

Countries

Estonia, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026